Cerevel Therapeutics announced June 29, 2021 the “CVL-231 Phase 1b Clinical Trial Results” for patients diagnosed with schizophrenia. They say the trial participants had statistically significant scores on the Positive and Negative Syndrome Scale (PANSS) compared to placebo.
CVL-231 is a muscarinic M4-selective Positive Allosteric Modulator. While that’s quite a mouthful, it basically means that it is supposed to reduce dopamine neurotransmitter activity in the brain.
The purpose of this new antipsychotic drug is the same as other dopamine-related antipsychotic drugs, but the emphasis with this drug is on reducing the side effects such as headaches, nausea, gastrointestinal upsets, exacerbation of psychotic symptoms, and debilitating movement disorders (e.g. akathisia, dyskinesia.)
They still don’t have a real clue about why messing with dopamine has any relationship to psychotic behavior, and as we’ve said before messing with neurotransmitters is playing Russian Roulette with your brain.
The PANSS Scale is used for assessing the severity of psychotic symptoms. The patient is rated by the opinion of an interviewer during a 45-minute interview covering 30 items about the patient’s symptoms on a scale of 1 (absent) to 7 (extreme).
The psychiatrist’s problem with side effects is that patients often stop taking the drugs because of the painful side effects and they relapse. The drugs don’t actually cure anything, they just temporarily relieve the pressure that an underlying problem may be causing, by breaking into the routine rhythmic flows and activities of the nervous system. Once the drug has worn off the original problem remains, and the body is worse off from the nerve damage.
Any medical doctor who takes the time to conduct a thorough physical examination of a child or adult exhibiting signs of what a psychiatrist fraudulently calls “schizophrenia” can find undiagnosed, untreated physical conditions. The correct action on a seriously mentally disturbed person is a full, searching clinical examination by a competent non-psychiatric medical doctor to discover and treat the true cause of the problem.
CCHR’s cofounder the late Professor Thomas Szasz stated that “schizophrenia is defined so vaguely that, in actuality, it is a term often applied to almost any kind of behavior of which the speaker disapproves.”
Today, psychiatry clings tenaciously to antipsychotics as the treatment for “schizophrenia,” despite their proven risks and studies which show that when patients stop taking these drugs, they improve.
No one denies that people can have difficult problems in their lives, that at times they can be mentally unstable, subject to unreasonable depression, anxiety or panic. Mental health care is therefore both valid and necessary. However, the emphasis must be on workable mental healing methods that improve and strengthen individuals and thereby society by restoring people to personal strength, ability, competence, confidence, stability, responsibility and spiritual well–being. Psychiatric drugs and psychiatric treatments are not workable.
Any person falsely diagnosed as mentally disordered which results in treatment that harms them should file a complaint with the police and professional licensing bodies and have this investigated. They should seek legal advice about filing a civil suit against any offending psychiatrist and his or her hospital, associations and teaching institutions seeking compensation.